157 related articles for article (PubMed ID: 29857115)
1. In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.
Pai AB; Pai MP; Meyer DE; Bales BC; Cotero VE; Zheng N; Jiang W
Regul Toxicol Pharmacol; 2018 Aug; 97():17-23. PubMed ID: 29857115
[TBL] [Abstract][Full Text] [Related]
2. Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations.
Pai AB; Meyer DE; Bales BC; Cotero VE; Pai MP; Zheng N; Jiang W
Clin Transl Sci; 2017 May; 10(3):194-200. PubMed ID: 28160427
[TBL] [Abstract][Full Text] [Related]
3. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
Pai AB
Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
[TBL] [Abstract][Full Text] [Related]
4. Iron Oxide Nanoparticle Formulations for Supplementation.
Pai AB
Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855107
[TBL] [Abstract][Full Text] [Related]
5. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
6. Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD).
Fütterer S; Andrusenko I; Kolb U; Hofmeister W; Langguth P
J Pharm Biomed Anal; 2013 Dec; 86():151-60. PubMed ID: 23998966
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
8. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.
Wu M; Sun D; Tyner K; Jiang W; Rouse R
Nanomaterials (Basel); 2017 Dec; 7(12):. PubMed ID: 29244729
[TBL] [Abstract][Full Text] [Related]
9. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury.
Rothman RJ; Serroni A; Farber JL
Mol Pharmacol; 1992 Oct; 42(4):703-10. PubMed ID: 1435746
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.
Brandis JEP; Kihn KC; Taraban MB; Schnorr J; Confer AM; Batelu S; Sun D; Rodriguez JD; Jiang W; Goldberg DP; Langguth P; Stemmler TL; Yu YB; Kane MA; Polli JE; Michel SLJ
Mol Pharm; 2021 Apr; 18(4):1544-1557. PubMed ID: 33621099
[TBL] [Abstract][Full Text] [Related]
11. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier.
Tyagi P; Kumar A; Gupta D; Singh H
AAPS PharmSciTech; 2017 Jan; 18(1):156-165. PubMed ID: 26912356
[TBL] [Abstract][Full Text] [Related]
12. Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina.
Sakamoto K; Suzuki T; Takahashi K; Koguchi T; Hirayama T; Mori A; Nakahara T; Nagasawa H; Ishii K
Exp Eye Res; 2018 Jun; 171():30-36. PubMed ID: 29530811
[TBL] [Abstract][Full Text] [Related]
13. Labile iron in parenteral iron formulations: a quantitative and comparative study.
Van Wyck D; Anderson J; Johnson K
Nephrol Dial Transplant; 2004 Mar; 19(3):561-5. PubMed ID: 14767009
[TBL] [Abstract][Full Text] [Related]
14. An extended-release formulation of desferrioxamine for subcutaneous administration.
Toliyat T; Jorjani M; Khorasanirad Z
Drug Deliv; 2009 Oct; 16(7):416-21. PubMed ID: 19640256
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations.
Span K; Pieters EHE; Brinks V; Hennink WE; Schellekens H
J Pharmacol Toxicol Methods; 2018; 91():7-17. PubMed ID: 29278742
[TBL] [Abstract][Full Text] [Related]
16. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Physicochemical Characterization.
Sun D; Rouse R; Patel V; Wu Y; Zheng J; Karmakar A; Patri AK; Chitranshi P; Keire D; Ma J; Jiang W
Nanomaterials (Basel); 2018 Jan; 8(1):. PubMed ID: 29303999
[TBL] [Abstract][Full Text] [Related]
17. Determination of Non-Transferrin Bound Iron, Transferrin Bound Iron, Drug Bound Iron and Total Iron in Serum in a Rats after IV Administration of Sodium Ferric Gluconate Complex by Simple Ultrafiltration Inductively Coupled Plasma Mass Spectrometric Detection.
Matta MK; Beekman CR; Gandhi A; Narayanasamy S; Thomas CD; Mohammad A; Stewart S; Xu L; Chockalingam A; Shea K; Patel V; Rouse R
Nanomaterials (Basel); 2018 Feb; 8(2):. PubMed ID: 29439469
[TBL] [Abstract][Full Text] [Related]
18. CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA.
Jahn MR; Mrestani Y; Langguth P; Neubert RH
Electrophoresis; 2007 Jul; 28(14):2424-9. PubMed ID: 17577885
[TBL] [Abstract][Full Text] [Related]
19. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics.
Funk F; Flühmann B; Barton AE
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216261
[TBL] [Abstract][Full Text] [Related]
20. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa.
Obolensky A; Berenshtein E; Lederman M; Bulvik B; Alper-Pinus R; Yaul R; Deleon E; Chowers I; Chevion M; Banin E
Free Radic Biol Med; 2011 Oct; 51(8):1482-91. PubMed ID: 21824515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
